Jakavi (Ruxolitinib)

Ruxolitinib blocks the activity of Janus kinase 1 and 2 (JAK1/JAK2), enzymes that transmit signals from cytokine receptors to the nucleus via the STAT pathway. By inhibiting this cascade, the drug reduces abnormal cell proliferation and dampens inflammatory signaling that underlies the listed hematologic and immune disorders.

The dose of Jakavi is individualized by the prescribing physician based on the specific indication, patient weight, blood‑count parameters and tolerability. Dosing may be adjusted over time, and any changes should be made only under medical supervision.

Safety of ruxolitinib in pregnancy and lactation has not been established. The product is classified as pregnancy category unknown, and it is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant.

To request Jakavi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Jakavi (ruxolitinib) is a first‑generation JAK1/JAK2 inhibitor, whereas alternatives such as fedratinib target JAK2 more selectively. Clinical data suggest comparable efficacy in myelofibrosis, but safety profiles differ; for example, fedratinib has a higher reported incidence of gastrointestinal toxicity, while ruxolitinib is more associated with cytopenias.

Jakavi tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat and direct sunlight to maintain product stability throughout its shelf life.

Jakavi is taken orally as a tablet, usually with water. It can be swallowed with or without food, but patients should follow the dosing schedule prescribed by their clinician and avoid crushing or chewing the tablet.

The most serious risks include severe or opportunistic infections, reactivation of hepatitis B, pulmonary hypertension, significant liver enzyme elevations, and the possible development of secondary malignancies. Patients should be monitored closely for signs of infection, respiratory symptoms, and abnormal laboratory values.

Jakavi is contraindicated in patients with severe hepatic impairment, active uncontrolled infections, and in pregnant women unless the benefit outweighs the risk. Caution is also advised for individuals with a history of severe cardiovascular disease or known hypersensitivity to ruxolitinib.